

# ECUADOR

## Cutaneous and mucosal Leishmaniasis 2018

Incidence  
(100,000 pop.) **10.2**

Transmission  
Triennium Leishmaniasis  
Composite Indicator  
(TLCIc 2016-2018) **Moderate**


Occurrence

**1237**

NEW CASES

1215 cutaneous (98.2%)

22 mucosal (1.8%)



**TLCIc triennium**  
(2016-2018)



### AGE GROUP

7% < 5 Y/O  
12.6% ≥ 5 < 10 Y/O  
80.4% > 10 Y/O

**19.6%** children  
under 10 years old



### GENDER

62.8% Male  
37.2% Female

**52.6%** men over 10  
years old



### CROSS-BORDER

Shares borders with  
**02** countries in **28**  
cantons

**23.6%** of the cases  
at the borders



### SURVEILLANCE AND CONTROL

**70%** of the population in  
transmission areas

**Increase** of the CL % in  
children under 10 Y/O  
compared to the previous  
year (Targets of the 2017-  
2022 Plan of Action)



### LEISHMANIA SPECIES

*L. amazonensis*  
*L. mexicana*  
*L. naiffi*  
*L. panamensis*  
*L. braziliensis*  
*L. guyanensis*  
*L. laisoni*



### LUTZOMYIA VECTORS

*L. ayacuchensis*, *L. carrerai*  
*L. carrerai*, *L. davisii*, *L.*  
*flaviscutellata*, *L. gomezi*, *L.*  
*hartmani*, *L. migonei*, *L.*  
*olmeca bicolor*, *L. panamensis*,  
*L. paraensis*, *L. salesi*, *L.*  
*sanguinaria*, *L. shannoni*, *L.*  
*trapidoi*, *L. ubiquitalis*, *L.*  
*ylephiletor*, *L. yuilli*



### PATIENT ASSISTANCE

Laboratory confirmation:  
**100%**

Cure rate: **61.2%**

% of cured patients among  
the treated: **61.2%**



### AVAILABLE MEDICINE

Meglumine  
Antimoniate

#### Source:

SisLeish - PAHO/WHO - Data provided by the Ministries of Health -  
National Leishmaniasis Programs  
Accessed on: 01 November 2019.

N/I: No information available; Y/O: years old